Cargando…

Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts

BACKGROUND: Articular manifestations are common in systemic lupus erythematosus (SLE) whereas erosive disease is not. Antibodies to cyclic citrullinated peptide (anti-CCP) are citrulline-dependent in rheumatoid arthritis (RA), whereas the opposite is suggested in SLE, as reactivity with cyclic argin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziegelasch, Michael, van Delft, Myrthe A. M., Wallin, Philip, Skogh, Thomas, Magro-Checa, César, Steup-Beekman, Gerda M., Trouw, Leendert A., Kastbom, Alf, Sjöwall, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135817/
https://www.ncbi.nlm.nih.gov/pubmed/27912793
http://dx.doi.org/10.1186/s13075-016-1192-x
_version_ 1782471614615519232
author Ziegelasch, Michael
van Delft, Myrthe A. M.
Wallin, Philip
Skogh, Thomas
Magro-Checa, César
Steup-Beekman, Gerda M.
Trouw, Leendert A.
Kastbom, Alf
Sjöwall, Christopher
author_facet Ziegelasch, Michael
van Delft, Myrthe A. M.
Wallin, Philip
Skogh, Thomas
Magro-Checa, César
Steup-Beekman, Gerda M.
Trouw, Leendert A.
Kastbom, Alf
Sjöwall, Christopher
author_sort Ziegelasch, Michael
collection PubMed
description BACKGROUND: Articular manifestations are common in systemic lupus erythematosus (SLE) whereas erosive disease is not. Antibodies to cyclic citrullinated peptide (anti-CCP) are citrulline-dependent in rheumatoid arthritis (RA), whereas the opposite is suggested in SLE, as reactivity with cyclic arginine peptide (CAP) is typically present. Antibodies targeting carbamylated proteins (anti-CarP) may occur in anti-CCP/rheumatoid factor (RF)-negative cases long before clinical onset of RA. We analysed these antibody specificities in sera from European patients with SLE in relation to phenotypes, smoking habits and imaging data. METHODS: Cases of SLE (n = 441) from Linköping, Sweden, and Leiden, the Netherlands, were classified according to American College of Rheumatology (ACR) and/or Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria. IgG anti-CCP, anti-CAP and anti-CarP were analysed by immunoassays. Radiographic data from 102 Swedish patients were available. RESULTS: There were 16 Linköping (6.8%) and 11 Leiden patients (5.4%) who were anti-CCP-positive, of whom approximately one third were citrulline-dependent: 40/441 (9.1%) were anti-CarP-positive, and 33% of the anti-CarP-positive patients were identified as anti-CCP-positive. No associations were found comparing anti-CCP or anti-CarP with ACR-defined phenotypes, immunologic abnormalities or smoking habits. Radiographically confirmed erosions were found in 10 patients, and were significantly associated with anti-CCP, anti-CarP and RF. Musculoskeletal ultrasonography scores were higher in anti-CCP-positive compared to anti-CCP-negative patients. CONCLUSIONS: In the hitherto largest anti-CarP study in SLE, we demonstrate that anti-CarP is more prevalent than anti-CCP and that the overlap is limited. We obtained some evidence that both autoantibodies seem to be associated with erosivity. Similar pathogenetic mechanisms to those seen in RA may be relevant in a subgroup of SLE cases with a phenotype dominated by arthritis.
format Online
Article
Text
id pubmed-5135817
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51358172016-12-15 Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts Ziegelasch, Michael van Delft, Myrthe A. M. Wallin, Philip Skogh, Thomas Magro-Checa, César Steup-Beekman, Gerda M. Trouw, Leendert A. Kastbom, Alf Sjöwall, Christopher Arthritis Res Ther Research Article BACKGROUND: Articular manifestations are common in systemic lupus erythematosus (SLE) whereas erosive disease is not. Antibodies to cyclic citrullinated peptide (anti-CCP) are citrulline-dependent in rheumatoid arthritis (RA), whereas the opposite is suggested in SLE, as reactivity with cyclic arginine peptide (CAP) is typically present. Antibodies targeting carbamylated proteins (anti-CarP) may occur in anti-CCP/rheumatoid factor (RF)-negative cases long before clinical onset of RA. We analysed these antibody specificities in sera from European patients with SLE in relation to phenotypes, smoking habits and imaging data. METHODS: Cases of SLE (n = 441) from Linköping, Sweden, and Leiden, the Netherlands, were classified according to American College of Rheumatology (ACR) and/or Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria. IgG anti-CCP, anti-CAP and anti-CarP were analysed by immunoassays. Radiographic data from 102 Swedish patients were available. RESULTS: There were 16 Linköping (6.8%) and 11 Leiden patients (5.4%) who were anti-CCP-positive, of whom approximately one third were citrulline-dependent: 40/441 (9.1%) were anti-CarP-positive, and 33% of the anti-CarP-positive patients were identified as anti-CCP-positive. No associations were found comparing anti-CCP or anti-CarP with ACR-defined phenotypes, immunologic abnormalities or smoking habits. Radiographically confirmed erosions were found in 10 patients, and were significantly associated with anti-CCP, anti-CarP and RF. Musculoskeletal ultrasonography scores were higher in anti-CCP-positive compared to anti-CCP-negative patients. CONCLUSIONS: In the hitherto largest anti-CarP study in SLE, we demonstrate that anti-CarP is more prevalent than anti-CCP and that the overlap is limited. We obtained some evidence that both autoantibodies seem to be associated with erosivity. Similar pathogenetic mechanisms to those seen in RA may be relevant in a subgroup of SLE cases with a phenotype dominated by arthritis. BioMed Central 2016-12-03 2016 /pmc/articles/PMC5135817/ /pubmed/27912793 http://dx.doi.org/10.1186/s13075-016-1192-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ziegelasch, Michael
van Delft, Myrthe A. M.
Wallin, Philip
Skogh, Thomas
Magro-Checa, César
Steup-Beekman, Gerda M.
Trouw, Leendert A.
Kastbom, Alf
Sjöwall, Christopher
Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
title Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
title_full Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
title_fullStr Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
title_full_unstemmed Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
title_short Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
title_sort antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined european cohorts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135817/
https://www.ncbi.nlm.nih.gov/pubmed/27912793
http://dx.doi.org/10.1186/s13075-016-1192-x
work_keys_str_mv AT ziegelaschmichael antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts
AT vandelftmyrtheam antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts
AT wallinphilip antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts
AT skoghthomas antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts
AT magrochecacesar antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts
AT steupbeekmangerdam antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts
AT trouwleenderta antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts
AT kastbomalf antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts
AT sjowallchristopher antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts